News Orders & Deals Tatva Chintan Pharma Files SEBI Takeover Disclosure for Promoter Share TransferTatva Chintan Pharma Files SEBI Takeover Disclosure for Promoter Share Transfer
Tatva Chintan Pharma Chem Limited has completed regulatory filings under SEBI Takeover Regulations for the transfer of 7,15,345 equity shares (3.06%) from Ajay Mansukhlal Patel (HUF) to the individual promoter following HUF dissolution. The transaction, executed without monetary consideration, increases the individual promoter's holding from 17.10% to 20.16% while maintaining overall promoter group commitment.
*this image is generated using AI for illustrative purposes only.
Tatva Chintan Pharma Chem Limited has filed a comprehensive disclosure under Regulation 10(6) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, following the completion of an inter-se transfer of equity shares between promoter entities. The transaction was executed on 06 February 2026, with formal disclosure submitted to stock exchanges on 09 February 2026.
Transaction Overview
The disclosure pertains to the transfer of 7,15,345 equity shares, representing 3.06% of the company's total issued and paid-up equity share capital. The shares were transferred from Ajay Mansukhlal Patel (HUF) to Ajay Mansukhlal Patel in his individual capacity as promoter, pursuant to the dissolution and full partition of the HUF entity.
| Transaction Parameter | Details |
|---|---|
| Shares Transferred | 7,15,345 equity shares |
| Percentage of Capital | 3.06% |
| Transaction Date | 06 February 2026 |
| Transferor | Ajay Mansukhlal Patel (HUF) |
| Acquirer | Ajay Mansukhlal Patel (Individual) |
| Consideration | Nil (HUF dissolution and partition) |
Regulatory Framework and Exemption
The acquisition was executed under the exemption provided in Regulation 10(1)(a)(ii) of the SEBI Takeover Regulations. Prior intimation under Regulation 10(5) was submitted to the exchanges on 29 January 2026, complying with the prescribed timeline requirements. The transaction qualifies as a family arrangement undertaken for succession planning and rationalization of family assets and business holdings.
Shareholding Pattern Changes
The transfer resulted in significant changes to the promoter shareholding structure while maintaining overall promoter group commitment to the pharmaceutical company.
| Entity | Pre-Transaction Holding | Post-Transaction Holding | Change |
|---|---|---|---|
| Ajay Mansukhlal Patel (HUF) | 7,15,345 shares (3.06%) | Nil (0.00%) | -7,15,345 shares |
| Ajay Mansukhlal Patel (Individual) | 40,00,000 shares (17.10%) | 47,15,345 shares (20.16%) | +7,15,345 shares |
Compliance and Documentation
Ajay Mansukhlal Patel, as the promoter and proposed acquirer, submitted the formal disclosure to both BSE Limited (Scrip Code: 543321) and National Stock Exchange of India Limited (Symbol: TATVA). The documentation confirms that no monetary consideration was involved in the transaction, as it formed part of the HUF dissolution process.
Corporate Structure Impact
This internal restructuring consolidates the shareholding under Ajay Mansukhlal Patel's individual ownership while maintaining the overall promoter group's stake in the company. The transfer represents a strategic reorganization of promoter holdings designed for smooth succession planning rather than any change in the fundamental promoter commitment to Tatva Chintan Pharma Chem Limited's operations and growth trajectory.
Historical Stock Returns for Tatva Chintan Pharma
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +2.42% | -1.41% | -12.11% | +16.14% | +75.02% | -47.52% |
17
